Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Spring Sale
Enjoy this offer
* See conditions under "Our services"

Valuation: Swedish Orphan Biovitrum AB

Capitalization 133B 14.46B 12.5B 11.28B 10.79B 19.67B 1,334B 20.22B 53.16B 638B 54.26B 53.12B 2,297B P/E ratio 2025
243x
P/E ratio 2026 * 23.5x
Enterprise value 144B 15.62B 13.5B 12.18B 11.65B 21.24B 1,440B 21.84B 57.41B 689B 58.61B 57.37B 2,481B EV / Sales 2025
4.06x
EV / Sales 2026 * 4.69x
Free-Float
51.66%
Yield 2025 *
-
Yield 2026 * -

Last Transcript: Swedish Orphan Biovitrum AB

1 day-0.72%
1 week-0.10%
Current month-2.43%
1 month-5.49%
3 months+15.86%
6 months+43.96%
Current year+15.93%
1 week 364.6
Extreme 364.6
392.8
1 month 364.6
Extreme 364.6
432.8
Current year 322
Extreme 322
432.8
1 year 241.8
Extreme 241.8
432.8
3 years 197.9
Extreme 197.9
432.8
5 years 127.1
Extreme 127.1
432.8
10 years 89.5
Extreme 89.5
432.8
Manager TitleAgeSince
Chief Executive Officer 61 2017-05-21
Director of Finance/CFO 59 2018-07-19
Chief Tech/Sci/R&D Officer 55 -
Director TitleAgeSince
Director/Board Member 57 2019-12-31
Director/Board Member 70 2020-12-31
Director/Board Member - -
Change 5d. change 1-year change 3-years change Capi.($)
-0.72%-0.10%+36.71%+61.09% 14.69B
+0.34%-1.63%+7.87%+3.70% 79.23B
-3.61%-3.53%+49.87%+216.38% 58.37B
+4.08%+65.70%+65.70%+65.70% 50.28B
-0.44%-3.07%-43.28%-49.86% 49.67B
+1.10%+0.28%+32.59%-25.76% 27.65B
+1.80%-3.17%+65.79%-59.53% 21.71B
-1.42%-4.25%+39.06%+31.45% 19.11B
-3.20%+4.02%+109.77%+108.16% 19.03B
-3.94%+7.29%+120.75%+407.75% 14.41B
Average -0.60%+0.39%+48.48%+75.91% 35.41B
Weighted average by Cap. -0.24%-0.58%+34.26%+59.80%

Financials

2025 2026 *
Net sales 28.43B 3.08B 2.66B 2.4B 2.3B 4.19B 284B 4.31B 11.33B 136B 11.57B 11.32B 490B 30.97B 3.36B 2.9B 2.62B 2.51B 4.57B 310B 4.7B 12.35B 148B 12.6B 12.34B 533B
Net income 633M 68.62M 59.29M 53.53M 51.19M 93.31M 6.33B 95.94M 252M 3.03B 257M 252M 10.9B 5.75B 623M 539M 486M 465M 848M 57.49B 872M 2.29B 27.49B 2.34B 2.29B 99.02B
Net Debt 10.68B 1.16B 1B 903M 864M 1.57B 107B 1.62B 4.26B 51.06B 4.35B 4.25B 184B 11.82B 1.28B 1.11B 1B 956M 1.74B 118B 1.79B 4.71B 56.51B 4.81B 4.71B 204B
Logo Swedish Orphan Biovitrum AB
Swedish Orphan Biovitrum AB (publ) is a Sweden-based pharmaceutical company. The Company develops, manufactures and sells medications within hemophilia, autoimmune diseases, metabolic diseases and cancer supportive care. The Company’s product portfolio is divided into three business segments: the Core Products segment offers pharmaceuticals within Inflammation area, and Genetics and metabolic therapeutic area; the Partner Products segment offers about 40 pharmaceuticals within hematology, oncology and emergency medicines, and the ReFacto Manufacturing segment. The Company has subsidiaries in Sweden, Denmark, Finland, Norway, United Kingdom and France, among others.
Employees
1,888
Date Price Change Volume
26-03-11 385.80 kr -0.72% 255,096
26-03-10 388.60 kr +3.41% 330,541
26-03-09 375.80 kr -0.21% 405,732
26-03-06 376.60 kr -1.21% 347,634
26-03-05 381.20 kr -1.29% 319,160
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
385.80SEK
Average target price
423.60SEK
Spread / Average Target
+9.80%

Quarterly revenue - Rate of surprise

SPRING SALE -40%: The Best Tools Reserved for Subscribers to Identify Tomorrow's Top Investments!
d
:
:
BENEFIT NOW